In a bid to improve transparency in 2014, the European Medical Agency’s December Management Board Meeting cleared the way for the publication of the agendas and minutes of the Agency’s Committee for Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for Veterinary Use (CVMP) and Committee for Advanced Therapies (CAT).
In a bid to improve transparency in 2014, the European Medical Agency’s December Management Board Meeting cleared the way for the publication of the agendas and minutes of the Agency’s Committee for Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for Veterinary Use (CVMP) and Committee for Advanced Therapies (CAT). This week the EMA will publish for the first time the agendas of the December meetings of these three committees. It will then become standard practice to publish all Committees’ agendas at the start of the meetings.
In agreeing its work program and €297.2 million budget for 2014, the Board predicted that next year will see “a slight general increase in its assessment activities for human medicines compared with 2013.” A 12% decrease in the number of initial marketing-authorization applications received is forecast, mainly due to a lower number of generic applications. The number of applications for new medicines containing a new active substance is expected to be stable. Activities in the early stages of medicines development, however, remain at a high level, and a 16% increase in the number of extensions of indications and variations applications is expected.
Further EMA priorities for 2014 include:
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.